The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site.

All material subject to strictly enforced copyright laws. © 2020 Euromoney, a part of the Euromoney Institutional Investor PLC.

If Sars doesn’t get you Sarbanes might

In a period when panics have outweighed optimism among investors, the Sars epidemic is just the latest in a series of shocks that have cast doubt on Asian companies’ ADR prospects. • Chris Cockerill reports

UNTIL A FEW weeks ago Asia offered a glimmer of hope in a gloomy global economy. The region seemed to offer a prospect of growth - especially in China - in welcome contrast to stagnation in Europe and the US. Asian companies and their bankers had looked forward to capital raising and making new investments. Then the first reports emerged of a virulent life-threatening illness spreading out from a focus in southern China.

In the wake of growing panic, Euromoney asks a banker what is ostensibly a simple question: what will investors be seeing from Asian corporates in the American depositary receipts market over the rest of the year? But it plainly poses him problems. There is an uncomfortably long pause as he attempts to organize his thoughts into a positive and upbeat answer.

Take out a complimentary trial

Take out a 7 day trial to gain unlimited access to and analysis and receive expertly-curated updates direct to your inbox.


Already a user?

Login now


We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree